Is angiogenesis essential for the progression of hematological malignancies or is it an epiphenomenon?
Ribatti
D
D
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D019898:Autocrine Communication; D001853:Bone Marrow / Q000098:blood supply; D016207:Cytokines / Q000502:physiology; D018450:Disease Progression; D016222:Fibroblast Growth Factor 2 / Q000502:physiology / Q000652:urine; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000652:urine; D006801:Humans; D008198:Lymph Nodes / Q000098:blood supply; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology*; D019899:Paracrine Communication
D020533:Angiogenesis Inhibitors; D016207:Cytokines; D016222:Fibroblast Growth Factor 2